

ForPatients

by Roche

Chronic Hepatitis B Hepatitis B Virus

A Trial To Evaluate The Efficacy And Safety Of Multiple Combination Therapies In Participants With Chronic Hepatitis B

Trial Status

Active, not recruiting

Trial Runs In

14 Countries

Trial Identifier

NCT04225715 2019-002086-35
WV41073

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This is a study designed to evaluate the safety, tolerability and efficacy of New Molecular Entity (NME) combination therapies in Chronic Hepatitis B (CHB) participants with preserved liver function and without significant fibrosis/cirrhosis. The platform design allows comparison of multiple NME combination therapies against a common control, and introduction of additional treatment arms at later study time points. Each arm will consist of a screening phase (up to 8 weeks), treatment phase (up to 48 weeks) and post-treatment follow-up phase (48 weeks). The safety and efficacy will be monitored throughout the study.

Hoffmann-La Roche

Sponsor

Phase 2

Phase

NCT04225715 2019-002086-35 WV41073

Trial Identifiers

Eligibility Criteria:

Gender

All

Age

>=18 Years & <= 65 Years

Healthy Volunteers

No
